Mirador Therapeutics

Immuno-fibrotic disease (private, $250M Series B)

Privately held: no public share price · United States

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 2
Undisclosed / early pipelineBiologic (subtype unspecified)
Inflammatory Bowel Disease
Ulcerative Colitis, Crohn's Disease
Phase 2
Undisclosed / early pipelineSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis, Crohn's Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
April 2027 (1)
MT-501 + MT-201Phase 2Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
Est. primary completion 2027-04-30 · NCT07113522 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.